Who are Sitagliptin plus metformin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapagliflozin/Sitagliptin, sitagliptin and acarbose, alogliptin + pioglitazone, Januvia (sitagliptin), Linagliptin / Metformin Oral Tablet, Metformin and Saxagliptin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sitagliptin-plus-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sitagliptin plus metformin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sitagliptin plus metformin (Sitagliptin plus metformin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor and biguanide. Area: Diabetes.

phase 3 DPP-4 inhibitor and biguanide DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Sitagliptin plus metformin (Sitagliptin plus metformin) — Merck Sharp & Dohme LLC. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin levels, enhancing glucose-dependent insulin secretion, and metformin, a biguanide, decreases hepatic glucose production and increases insulin sensitivity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sitagliptin plus metformin TARGET	Sitagliptin plus metformin	Merck Sharp & Dohme LLC	phase 3	DPP-4 inhibitor and biguanide	DPP-4
Dapagliflozin/Sitagliptin	Dapagliflozin/Sitagliptin	Boryung Pharmaceutical Co., Ltd	marketed	SGLT2 inhibitor / DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
sitagliptin and acarbose	sitagliptin and acarbose	Nanjing First Hospital, Nanjing Medical University	marketed	DPP-4 inhibitor + alpha-glucosidase inhibitor combination	DPP-4 enzyme; alpha-glucosidase enzymes
alogliptin + pioglitazone	alogliptin + pioglitazone	Kun-Ho Yoon	marketed	DPP-4 inhibitor + thiazolidinedione	DPP-4 and PPAR-γ
Januvia (sitagliptin)	Januvia (sitagliptin)	Zealand University Hospital	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)
Linagliptin / Metformin Oral Tablet	Linagliptin / Metformin Oral Tablet	Universidad de Guanajuato	marketed	DPP-4 inhibitor / Biguanide combination	DPP-4 (dipeptidyl peptidase-4) / AMPK pathway
Metformin and Saxagliptin	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor and biguanide class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sitagliptin plus metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/sitagliptin-plus-metformin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing